Revision 18 of TİTCK’s Guideline on the Labelling and Package Leaflets of Human Medicinal Products (İRD-KLVZ-07), dated 11 August 2026, sets out the final rules for the electronic package leaflet (e-KT, ePIL). Under Transitional Article 3 of the guideline, the ePIL obligations apply from 1 January 2027 . From that date, products in scope must carry an ePIL.
Which products are in scope?
The rule is broad: an ePIL is mandatory for all human medicinal products, with three exceptions:
- Products intended to be administered only by healthcare professionals (including those supplied through pharmacies, e.g. vaccines, radiopharmaceuticals, hospital products)
- Products that qualify as small packages under the Regulation on the Labelling, Package Leaflet and Tracking of Human Medicinal Products
- Products without an outer carton
Does the printed PIL disappear?
No, it becomes optional. In the guideline’s words, the ePIL is mandatory and the printed leaflet is optional. A printed PIL may still be included in the pack, but every product must have at least one leaflet, printed or electronic.
Companies that keep a printed PIL for products with a QR code on the carton must add the statement directing patients to scan the code for detailed and up-to-date information.
Technical conditions for the ePIL
Section 2.11/A of the guideline lists the following conditions:
- The ePIL is accessed through a QR code on the outer carton. This can be part of the multimedia QR code defined in the guideline or a separate, stand-alone QR code.
- The ePIL must match the current approved PIL. When the PIL is updated, the ePIL must be updated within 30 days of approval of the new PIL.
- The QR code must not, by its size or position, impair the legibility of other information on the pack.
- The QR code must be accompanied by the statement “Bilgilendirme medyası için kodu okutunuz.” (scan the code for information media).
- Users must be able to reach the ePIL by scanning a single QR code with the device camera, without installing any additional software.
- No permission other than personal data protection (KVKK) consent may be requested when accessing the ePIL.
- The ePIL may be a PDF or HTML document, but the whole leaflet may not be a single image (jpg, png, etc.).
- The MAH must submit an undertaking that the ePIL content is identical to the current approved PIL.
- The website hosting the ePIL must be live before the application is submitted to TİTCK.
What to complete before 1 January 2027
Based on these conditions, we summarise the steps companies need to complete:
- Portfolio screening: scope check for each product (HCP-administered, small pack, no outer carton) and a list of products that need an ePIL.
- Printed PIL decision: whether to keep the printed leaflet, and if so, adding the mandatory statement to the PIL text.
- Hosting: a website for the ePILs that needs no app, asks for no permission other than KVKK, and is live before submission.
- Content conversion: a text-based PDF or HTML ePIL produced from the approved PIL. HTML is the better option for readability and accessibility on phones.
- Artwork update: position and size of the QR code on the carton and the required statement next to it.
- Undertaking and submission: the undertaking that the ePIL matches the approved PIL, and the application to TİTCK.
- Update procedure: an internal procedure that ensures the ePIL is updated within 30 days of each PIL approval.
A QR code linking to an audio PIL for visually impaired patients remains optional. If used, it can sit within the multimedia QR code or be a separate code, and it must also be updated within 30 days of a PIL update.
Source: TİTCK, Guideline on the Labelling and Package Leaflets of Human Medicinal Products (İRD-KLVZ-07), Rev. 18, 11.08.2026; Part 2, sections 2.11 and 2.11/A, and Transitional Article 3. This article is for general information; current legislation and TİTCK announcements prevail.
